IRLAB Therapeutics – executive interview

Based in Sweden, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases using its ISP technology platform. Its two lead assets, mesdopetam and pirepemat, are in clinical development for the symptomatic treatment of Parkinson’s disease. Mesdopetam is a D3 receptor antagonist that has recently concluded its Phase IIb trial (PD-LIDs study) for levodopa-induced dyskinesia. Pirepemat (in Phase IIb) is a first-in-class drug designed to strengthen nerve-cell signalling in the prefrontal cortex and is being developed for postural dysfunction and falls in Parkinson’s disease. Following the reporting of statistically significant efficacy in the secondary endpoint in the PD-LIDs study, management has confirmed plans to advance mesdopetam to Phase III studies.

In this video, Dr Gunnar Olsson, IRLAB Therapeutics’ CEO, and Dr Nicholas Waters, head of R&D, provide a detailed overview of the clinical development of mesdopetam and pirepemat.